Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2016 - 2021)

Historic Long-Term Deferred Tax for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Q2 2021 value amounting to $345000.0.

  • Enanta Pharmaceuticals' Long-Term Deferred Tax fell 9774.35% to $345000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $345000.0, marking a year-over-year decrease of 9774.35%. This contributed to the annual value of $345000.0 for FY2020, which is 9695.79% down from last year.
  • As of Q2 2021, Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $345000.0, which was down 9774.35% from $345000.0 recorded in Q1 2021.
  • Enanta Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $17.7 million during Q2 2017, with a 5-year trough of $345000.0 in Q3 2020.
  • For the 5-year period, Enanta Pharmaceuticals' Long-Term Deferred Tax averaged around $8.5 million, with its median value being $9.2 million (2018).
  • In the last 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax surged by 20332.02% in 2017 and then crashed by 9774.35% in 2021.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $7.6 million in 2017, then rose by 22.2% to $9.2 million in 2018, then grew by 15.22% to $10.7 million in 2019, then crashed by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
  • Its last three reported values are $345000.0 in Q2 2021, $345000.0 for Q1 2021, and $345000.0 during Q4 2020.